Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-17

Study Completion Date

2022-05-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Palliative Care is active holistic care offered to people who are in intense suffering related to their health, resulting from a serious life-threatening illness, with a focus on improving the quality of life. Among the symptoms that cause suffering, physical pain has a prominent role in terms of prevalence and impact on well-being, especially in the subgroup of patients with terminal cancer. Myofascial Pain Syndrome may be one of the components of pain in cancer patients in palliative care. However, the literature is scarce in defining the prevalence of this condition in this population, and there is no evidence of the benefit of needling treatment with 1% lidocaine in these patients until now. The objectives of this study are to determinate the prevalence of myofascial pain syndrome and to evaluate the effectiveness of myofascial pain treatment with 1% lidocaine injection in reducing pain in palliative cancer patients, comparing it with a control group in usual care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Manual Therapy Treatment for Myofascial Pain

NCT01381380

Myofascial Pain Syndromes

COMPLETED NA

Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

NCT04732507

Myofascial Pain Myofascial Trigger Point Pain

ENROLLING_BY_INVITATION PHASE2

Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.

NCT01250184

Myofascial Pain Syndrome Pain Myofascial Trigger Point Pain +1 more

COMPLETED PHASE4

Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome

NCT02179320

Myofascial Pain Syndrome

COMPLETED NA

Immediate Stiffness Changes in Myofascial Trigger Points After Dry Needling

NCT04832074

Myofascial Pain Syndrome Neck Pain Trigger Point Pain, Myofascial

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a clinical trial designed as a comparative, randomized, single-blinded intervention study. Patients will be recruited from wards and radiotherapy sector of the Ribeirão Preto Clinical Hospital - Ribeirão Preto Medical School, University of São Paulo (FMRP-USP). Initially, patients aged 50 years or older with cancer in palliative care will be evaluated to assess the prevalence of myofascial pain syndrome using Travel and Simons' diagnostic criteria and for the following variables: demographic characteristics, functional status (Palliative Performance Scale), pain intensity (visual analog scale and pain threshold measurement with a pressure gauge), prognostic score (Palliative Prognosis Score), depression and anxiety (Hospital Anxiety and Depression Scale), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL) and analgesic drugs in use. The participants that (1) accomplish the Travel and Simons' diagnostic criteria for myofascial pain syndrome, (2) have performance status on the Karnofsky scale of 30 or more, and (3) have pain intensity on visual analog scale of 5 or more will be randomized for the clinical trial. The sample size calculation resulted in 15 participants for each group, totaling a sample composed of 30 patients. The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine, and the control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors. Both groups will be reevaluated after 72 hours and 1 week after the procedure. In the analysis statistics, chi-square test (or Fisher's exact test) will be used to evaluate categorical variables. For the comparison between the groups at each moment (before and after intervention) will be used the linear mixed effects model. The significance level established was \<0.05. SAS Statistical Software (version 9.3; SAS Institute, Inc. Cary , NC) will be used for the analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myofascial Pain Syndromes Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, comparative, single-blinded interventional study

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

A member of the research team who doesn´t know whether the participant is in the intervention or control group will be responsible for the reassessment (after 72 hours and 1 week) to measure the outcomes

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1% lidocaine injection

The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention

Group Type EXPERIMENTAL

1% lidocaine injection in trigger points

Intervention Type COMBINATION_PRODUCT

The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention

Control Group

The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1% lidocaine injection in trigger points

The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants that

1. accomplish the Travel and Simons' diagnostic criteria for myofascial pain syndrome,
2. have pain intensity on visual analog scale of 5 or more,
3. have performance status on the Karnofsky Performance Status scale of 30 or more.

Exclusion Criteria

* Use of high dose anticoagulants (RNI above the therapeutic range);
* Patients with hemorrhagic diathesis;
* Patients with moderate to severe dementia syndrome;
* Patients with diagnosis of acute confusional state during the follow-up;
* Occurrence of clinical complication or intervention that could compromise the reevaluation of pain in the following days (for example, undergoing a surgical procedure or nerve block) or death.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No